Abstract：
OBJECTIVE: To investigate the value of 18F-FDG PET/CT in diagnosis and disease evaluation of Langerhans cell histiocytosis (LCH).
METHODS: A retrospective analysis of 31 patients with LCH confirmed by histopathology was performed. A systematic analysis of the PET/CT imaging manifestations of LCH was performed, recording patients who were treated and receiving PET/CT for efficacy evaluation. In addition, clinical and laboratory data of LCH patients were collected, and the correlation between these data and PET/CT metabolic parameters was initially investigated.
RESULTS: Of the 31 patients, thirty had at least 1 PET/CT positive lesions (96.7%), and one had only skin damage without abnormalities on PET/CT. Of 31 patients, fifteen (48.4%) had single system (SS) disease (9 cases with a single site and 6 cases with multiple sites) and 16 (51.6%) had multisystem (MS) disease (6 low risk and 10 high risk cases). The incidence of LCH lesions in the bone, lymphatic system, pituitary gland, liver, soft tissue, thyroid gland, thymus, and lungs was 20 cases (64.5%), 12 cases (38.7%), 3 cases (9.7%), 2 cases (6.5%), 2 cases (6.5%), 1 case (3.2%), 1 case (3.2%), and 8 cases (25.8%), respectively. A total of 21 PET/CT follow-up scanning were performed in 13 patients receiving chemotherapy, with 13 (61.9%) partial metabolic remission (PMR), 6 (28.6%) progressive metabolic disease (PMD), and 2 (9.5%) stable metabolic disease (SMD), according to PET Response Evaluation Criteria in Solid Tumors (PRECIST) 1.0. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and Lactic Dehydrogenase (LDH) were positively correlated with TTLG (total TLG) (R2 = 0.3256, 0.2409, 0.4205, P < 0.05). The Re-examine SUVmax is positively correlated with re-examine LDH (R2 = 0.7285, P < 0.05).
CONCLUSIONS: 18F-FDG PET/CT is an effective way to diagnose and evaluate LCH. PET metabolic parameters were associated with laboratory inflammatory markers, suggesting that 18F-FDG PET/CT may be helpful in evaluating disease activity of LCH.
METHODS: A retrospective analysis of 31 patients with LCH confirmed by histopathology was performed. A systematic analysis of the PET/CT imaging manifestations of LCH was performed, recording patients who were treated and receiving PET/CT for efficacy evaluation. In addition, clinical and laboratory data of LCH patients were collected, and the correlation between these data and PET/CT metabolic parameters was initially investigated.
RESULTS: Of the 31 patients, thirty had at least 1 PET/CT positive lesions (96.7%), and one had only skin damage without abnormalities on PET/CT. Of 31 patients, fifteen (48.4%) had single system (SS) disease (9 cases with a single site and 6 cases with multiple sites) and 16 (51.6%) had multisystem (MS) disease (6 low risk and 10 high risk cases). The incidence of LCH lesions in the bone, lymphatic system, pituitary gland, liver, soft tissue, thyroid gland, thymus, and lungs was 20 cases (64.5%), 12 cases (38.7%), 3 cases (9.7%), 2 cases (6.5%), 2 cases (6.5%), 1 case (3.2%), 1 case (3.2%), and 8 cases (25.8%), respectively. A total of 21 PET/CT follow-up scanning were performed in 13 patients receiving chemotherapy, with 13 (61.9%) partial metabolic remission (PMR), 6 (28.6%) progressive metabolic disease (PMD), and 2 (9.5%) stable metabolic disease (SMD), according to PET Response Evaluation Criteria in Solid Tumors (PRECIST) 1.0. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and Lactic Dehydrogenase (LDH) were positively correlated with TTLG (total TLG) (R2 = 0.3256, 0.2409, 0.4205, P < 0.05). The Re-examine SUVmax is positively correlated with re-examine LDH (R2 = 0.7285, P < 0.05).
CONCLUSIONS: 18F-FDG PET/CT is an effective way to diagnose and evaluate LCH. PET metabolic parameters were associated with laboratory inflammatory markers, suggesting that 18F-FDG PET/CT may be helpful in evaluating disease activity of LCH.
摘要：
目的：探讨18F-FDGPET/CT在朗格汉斯细胞组织细胞增生症(LCH)诊断及病情评估中的价值。
方法：对31例经组织病理学证实的LCH患者进行回顾性分析。对LCH的PET/CT影像学表现进行了系统分析，记录接受治疗的患者并接受PET/CT进行疗效评估。此外,收集LCH患者的临床和实验室数据,并初步研究了这些数据与PET/CT代谢参数之间的相关性。
结果：在31例患者中，30例PET/CT阳性病灶至少1例（96.7%），1例仅皮肤损伤，PET/CT无异常。31名患者中,单系统（SS）疾病15例（48.4％）（单部位9例，多部位6例），多系统（MS）疾病16例（51.6％）（低风险6例，高危10例）。骨骼中LCH病变的发生率，淋巴系统,脑垂体,肝脏,软组织,甲状腺,胸腺,肺20例(64.5%)，12例（38.7%），3例(9.7%)，2例（6.5%），2例（6.5%），1例（3.2%），1例（3.2%），8例(25.8%)，分别。13例化疗患者共进行21次PET/CT随访扫描,13（61.9%）部分代谢缓解（PMR），6（28.6%）进行性代谢性疾病（PMD），2例(9.5%)稳定代谢性疾病(SMD)，根据实体瘤的PET反应评估标准（PRECIST）1.0。红细胞沉降率(ESR),C反应蛋白(CRP)、乳酸脱氢酶(LDH)与TTLG(总TLG)呈正相关(R2=0.3256、0.2409、0.4205,P<0.05)。再次检查SUVmax与再次检查LDH呈正相关(R2=0.7285,P<0.05)。
结论：18F-FDGPET/CT是诊断和评估LCH的有效方法。PET代谢参数与实验室炎症标志物相关，提示18F-FDGPET/CT可能有助于评估LCH的疾病活动性。
方法：对31例经组织病理学证实的LCH患者进行回顾性分析。对LCH的PET/CT影像学表现进行了系统分析，记录接受治疗的患者并接受PET/CT进行疗效评估。此外,收集LCH患者的临床和实验室数据,并初步研究了这些数据与PET/CT代谢参数之间的相关性。
结果：在31例患者中，30例PET/CT阳性病灶至少1例（96.7%），1例仅皮肤损伤，PET/CT无异常。31名患者中,单系统（SS）疾病15例（48.4％）（单部位9例，多部位6例），多系统（MS）疾病16例（51.6％）（低风险6例，高危10例）。骨骼中LCH病变的发生率，淋巴系统,脑垂体,肝脏,软组织,甲状腺,胸腺,肺20例(64.5%)，12例（38.7%），3例(9.7%)，2例（6.5%），2例（6.5%），1例（3.2%），1例（3.2%），8例(25.8%)，分别。13例化疗患者共进行21次PET/CT随访扫描,13（61.9%）部分代谢缓解（PMR），6（28.6%）进行性代谢性疾病（PMD），2例(9.5%)稳定代谢性疾病(SMD)，根据实体瘤的PET反应评估标准（PRECIST）1.0。红细胞沉降率(ESR),C反应蛋白(CRP)、乳酸脱氢酶(LDH)与TTLG(总TLG)呈正相关(R2=0.3256、0.2409、0.4205,P<0.05)。再次检查SUVmax与再次检查LDH呈正相关(R2=0.7285,P<0.05)。
结论：18F-FDGPET/CT是诊断和评估LCH的有效方法。PET代谢参数与实验室炎症标志物相关，提示18F-FDGPET/CT可能有助于评估LCH的疾病活动性。
